// App-Quantinova.ai

3419 : Reduction in Initial Length of Stay with Rivaroxaban Single-Drug Regimen versus LMWH-VKA Standard of Care: Findings from the EINSTEIN Trial Program

Researchers

Presenter

  • Martin Prins

Principal Investigators

  • Luke Bamber

  • Maria Wang

  • Anthonie WA Lensing

Medical Centers

  • Beneficencia Portuguesa Sao Paulo and Universidade Estadual de Campinas UNICAMP, Sao Paulo, Brazil,

  • Clinical Epidemiology and Technology Assessment, University Medical Center, Maastricht, Netherlands

Locations

  • Brazil

  • Netherlands

Companies

  • Bayer

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Deep vein thrombosis

  • Pulmonary embolism

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Heparin

  • Fondaparinux sodium

  • rivaroxaban

  • Enoxaparin

  • Enoxaparin sodium

  • Hydroxyzine

  • Warfarin

  • Heparin

Outcome

  • N/A

Study Design

  • open label

  • randomized

  • double blind/blinded

  • non inferiority

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved